Emerging Trends in the Management of Brain Metastases from Non-small Cell Lung Cancer.

Publication/Presentation Date

5-7-2018

Abstract

PURPOSE OF REVIEW: To summarize current approaches in the management of brain metastases from non-small cell lung cancer (NSCLC).

RECENT FINDINGS: Local treatment has evolved from whole-brain radiotherapy (WBRT) to increasing use of stereotactic radiosurgery (SRS) alone for patients with limited (1-4) brain metastases. Trials have established post-operative SRS as an alternative to adjuvant WBRT following resection of brain metastases. Second-generation TKIs for ALK rearranged NSCLC have demonstrated improved CNS penetration and activity. Current brain metastasis trials are focused on reducing cognitive toxicity: hippocampal sparing WBRT, SRS for 5-15 metastases, pre-operative SRS, and use of systemic targeted agents or immunotherapy. The role for radiotherapy in the management of brain metastases is becoming better defined with local treatment shifting from WBRT to SRS alone for limited brain metastases and post-operative SRS for resected metastases. Further trials are warranted to define the optimal integration of newer systemic agents with local therapies.

Volume

20

Issue

7

First Page

54

Last Page

54

ISSN

1534-6269

Disciplines

Medicine and Health Sciences | Oncology

PubMedID

29736685

Department(s)

Department of Radiation Oncology

Document Type

Article

Link to Full Text

Share

COinS